Top

Osteoporosis International

Published in:

01-04-2008 | Rewiev

Strategies to reverse bone loss in women with functional hypothalamic amenorrhea: a systematic review of the literature

Authors: J. D. Vescovi, S. A. Jamal, M. J. De Souza

Published in: Osteoporosis International | Issue 4/2008

Abstract

Summary

Functional hypothalamic amenorrhea (FHA) impairs the attainment of peak bone mass and as such can increase the risk of fractures later in life. To document available treatment strategies, we conducted a systematic review of the literature. We report that hormonal therapies have limited effectiveness in increasing bone mass, whereas increased caloric intake resulting in weight gain and/or resumption of menses is an essential strategy for restoring bone mass in women with FHA.

Introduction

Women with functional hypothalamic amenorrhea (FHA) may not achieve peak bone mass (PBM), which increases the risk of stress fractures, and may increase the risk of osteoporotic fractures in later life.

Methods

To identify effective treatment strategies for women with FHA, we conducted a systematic review of the literature. We included randomized controlled trials (RCTs), cross-sectional studies, and case studies that reported on the effects of pharmacological and non-pharmacological interventions on bone mineral density (BMD) or bone turnover in women with FHA.

Results

Most published studies (n = 26) were designed to treat the hormonal abnormities observed in women with FHA (such as low estrogen, leptin, insulin-like growth factor-1, and DHEA); however none of these treatments demonstrated consistent improvements in BMD. Therapies containing an estrogen given for 8–24 months resulted in variable improvements (1.0–19.0%) in BMD, but failed to restore bone mass to that of age-matched controls. Three studies reported on the use of bisphosphonates (3–12 months) in anorexic women, which appear to have limited effectiveness to improve BMD compared to nutritional treatments. Another three investigations showed no improvements in BMD after androgen therapy (DHEA and testosterone) in anorexic women. In contrast, reports (n = 9) describing an increase in caloric intake that results in weight gain and/or the resumption of menses reported a 1.1–16.9% increase in BMD concomitant with an improvement in bone formation and reduction in bone resorption markers.

Conclusions

Our literature review indicates that the most successful, and indeed essential strategy for improving BMD in women with FHA is to increase caloric intake such that body mass is increased and there is a resumption of menses. Further long-term studies to determine the persistence of this effect and to determine the effects of this and other strategies on fracture risk are needed.

Warren MP, Brooks-Gunn J, Fox RP, Holderness CC, Hyle EP, Hamilton WG (2002) Osteopenia in exercise-associated amenorrhea using ballet dancers as a model: a longitudinal study. J Clin Endocrinol Metab 87:3162–3168PubMedCrossRef

Grinspoon S, Miller K, Coyle C, Krempin J, Armstrong C, Pitts S, Herzog D, Klibanski A (1999) Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab 84:2049–2055PubMedCrossRef

Grinspoon S, Thomas E, Pitts S, Gross E, Mickley D, Miller K, Herzog D, Klibanski A (2000) Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med 133:790–794PubMed

De Souza MJ, Williams NI (2004) Physiological aspects and clinical sequelae of energy deficiency and hypoestrogenism in exercising women. Hum Reprod Updat 10:433–448CrossRef

Loucks AB, Verdun M, Heath EM (1998) Low energy availability, not stress of exercise, alters LH pulsatility in exercising women. J Appl Physiol 84:37–46PubMed

Riggs BL, Khosla S, Melton LJ 3rd (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279–302PubMedCrossRef

Riggs BL (2000) The mechanisms of estrogen regulation of bone resorption. J Clin Invest 106:1203–1204PubMedCrossRef

Valentino R, Savastano S, Tommaselli AP, D’Amore G, Dorato M, Lombardi G (2001) The influence of intense ballet training on trabecular bone mass, hormone status, and gonadotropin structure in young women. J Clin Endocrinol Metab 86:4674–4678PubMedCrossRef

Bass SL, Eser P, Daly R (2005) The effect of exercise and nutrition on the mechanostat. J Musculoskelet Neuronal Interact 5:239–254PubMed

10.

Joy EA, Campbell D (2005) Stress fractures in the female athlete. Curr Sports Med Rep 4:323–328PubMedCrossRef

11.

Berga SL, Loucks TL (2005) The diagnosis and treatment of stress-induced anovulation. Minerva Ginecol 57:45–54PubMed

12.

Seeman E, Szmukler GI, Formica C, Tsalamandris C, Mestrovic R (1992) Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise. J Bone Miner Res 7:1467–1474PubMedCrossRef

13.

Laughlin GA, Yen SS (1996) Nutritional and endocrine-metabolic aberrations in amenorrheic athletes. J Clin Endocrinol Metab 81:4301–4309PubMedCrossRef

14.

Liu SL, Lebrun CM (2006) Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review. Br J Sports Med 40:11–24PubMedCrossRef

15.

Rickenlund A, Carlstrom K, Ekblom B, Brismar TB, Von Schoultz B, Hirschberg AL (2004) Effects of oral contraceptives on body composition and physical performance in female athletes. J Clin Endocrinol Metab 89:4364–4370PubMedCrossRef

16.

De Cree C, Lewin R, Ostyn M (1988) Suitability of cyproterone acetate in the treatment of osteoporosis associated with athletic amenorrhea. Int J Sports Med 9:187–192PubMed

17.

Cumming DC (1996) Exercise-associated amenorrhea, low bone density, and estrogen replacement therapy. Arch Intern Med 156:2193–2195PubMedCrossRef

18.

Warren MP, Miller KK, Olson WH, Grinspoon SK, Friedman AJ (2005) Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study. Contraception 72:206–211PubMedCrossRef

19.

Karlsson MK, Weigall SJ, Duan Y, Seeman E (2000) Bone size and volumetric density in women with anorexia nervosa receiving estrogen replacement therapy and in women recovered from anorexia nervosa. J Clin Endocrinol Metab 85:3177–3182PubMedCrossRef

20.

Gremion G, Rizzoli R, Slosman D, Theintz G, Bonjour JP (2001) Oligo-amenorrheic long-distance runners may lose more bone in spine than in femur. Med Sci Sports Exerc 33:15–21PubMed

21.

Castelo-Branco C, Vicente JJ, Pons F, Martinez de Osaba MJ, Casals E, Vanrell JA (2001) Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. J Reprod Med 46:875–879PubMed

22.

Gibson JH, Mitchell A, Reeve J, Harries MG (1999) Treatment of reduced bone mineral density in athletic amenorrhea: a pilot study. Osteoporos Int 10:284–289PubMedCrossRef

23.

Warren MP, Brooks-Gunn J, Fox RP, Holderness CC, Hyle EP, Hamilton WG, Hamilton L (2003) Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: a longitudinal study. Fertil Steril 80:398–404PubMedCrossRef

24.

Golden NH, Lanzkowsky L, Schebendach J, Palestro CJ, Jacobson MS, Shenker IR (2002) The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J Pediatr Adolesc Gynecol 15:135–143PubMedCrossRef

25.

Munoz MT, Morande G, Garcia-Centenera JA, Hervas F, Pozo J, Argente J (2002) The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa. Eur J Endocrinol 146:45–50PubMedCrossRef

26.

Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC (1995) The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab 80:898–904PubMedCrossRef

27.

Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS (2002) Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab 87:4935–4941PubMedCrossRef

28.

Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A (2002) Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 87:2883–2891PubMedCrossRef

29.

Strokosch GR, Friedman AJ, Wu SC, Kamin M (2006) Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. J Adolesc Health 39:819–827PubMedCrossRef

30.

Hergenroeder AC, Smith EO, Shypailo R, Jones LA, Klish WJ, Ellis K (1997) Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Am J Obstet Gynecol 176:1017–1025PubMedCrossRef

31.

Grinspoon SK, Friedman AJ, Miller KK, Lippman J, Olson WH, Warren MP (2003) Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea. J Clin Endocrinol Metab 88:3651–3656PubMedCrossRef

32.

Garnero P, Sornay-Rendu E, Delmas PD (1995) Decreased bone turnover in oral contraceptive users. Bone 16:499–503PubMedCrossRef

33.

Nappi C, Di Spiezio Sardo A, Acunzo G, Bifulco G, Tommaselli GA, Guida M, Di Carlo C (2003) Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 67:355–359PubMedCrossRef

34.

Paoletti AM, Orru M, Lello S, Floris S, Ranuzzi F, Etzi R, Zedda P, Guerriero S, Fratta S, Sorge R, Mallarini G, Melis GB (2004) Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women. Contraception 70:293–298PubMedCrossRef

35.

Wreje U, Brynhildsen J, Aberg H, Bystrom B, Hammar M, von Schoultz B (2000) Collagen metabolism markers as a reflection of bone and soft tissue turnover during the menstrual cycle and oral contraceptive use. Contraception 61:265–270PubMedCrossRef

36.

Harel Z, Riggs S (1997) Transdermal versus oral administration of estrogen in the management of lumbar spine osteopenia in an adolescent with anorexia nervosa. J Adolesc Health 21:179–182PubMedCrossRef

37.

Patel S (1999) Effect of hormone replacement therapy on bone density in a patient with severe osteoporosis caused by anorexia nervosa. Ann Rheum Dis 58:66PubMedCrossRef

38.

Gordon CM, Grace E, Emans SJ, Goodman E, Crawford MH, Leboff MS (1999) Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa. J Bone Miner Res 14:136–145PubMedCrossRef

39.

Miller KK, Grieco KA, Klibanski A (2005) Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab 90:1428–1433PubMedCrossRef

40.

Grinspoon SK, Baum HB, Peterson S, Klibanski A (1995) Effects of rhIGF-I administration on bone turnover during short-term fasting. J Clin Invest 96:900–906PubMedCrossRef

41.

Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A (1996) Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab 81:3864–3870PubMedCrossRef

42.

Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS (2004) Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 351:987–997PubMedCrossRef

43.

Nakahara T, Nagai N, Tanaka M, Muranaga T, Kojima S, Nozoe S, Naruo T (2006) The effects of bone therapy on tibial bone loss in young women with anorexia nervosa. Int J Eat Disord 39:20–26PubMedCrossRef

44.

Miller KK, Grieco KA, Mulder J, Grinspoon S, Mickley D, Yehezkel R, Herzog DB, Klibanski A (2004) Effects of risedronate on bone density in anorexia nervosa. J Clin Endocrinol Metab 89:3903–3906PubMedCrossRef

45.

Golden NH, Iglesias EA, Jacobson MS, Carey D, Meyer W, Schebendach J, Hertz S, Shenker IR (2005) Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 90:3179–3185PubMedCrossRef

46.

Holtkamp K, Mika C, Grzella I, Heer M, Pak H, Hebebrand J, Herpertz-Dahlmann B (2003) Reproductive function during weight gain in anorexia nervosa. Leptin represents a metabolic gate to gonadotropin secretion. J Neural Transm 110:427–435PubMedCrossRef

47.

Loucks AB, Verdun M (1998) Slow restoration of LH pulsatility by refeeding in energetically disrupted women. Am J Physiol 275:R1218–R1226PubMed

48.

Heer M, Mika C, Grzella I, Drummer C, Herpertz-Dahlmann B (2002) Changes in bone turnover in patients with anorexia nervosa during eleven weeks of inpatient dietary treatment. Clin Chem 48:754–760PubMed

49.

Herpertz S, Albers N, Wagner R, Pelz B, Kopp W, Mann K, Blum WF, Senf W, Hebebrand J (2000) Longitudinal changes of circadian leptin, insulin and cortisol plasma levels and their correlation during refeeding in patients with anorexia nervosa. Eur J Endocrinol 142:373–379PubMedCrossRef

50.

Holtkamp K, Hebebrand J, Mika C, Grzella I, Heer M, Heussen N, Herpertz-Dahlmann B (2003) The effect of therapeutically induced weight gain on plasma leptin levels in patients with anorexia nervosa. J Psychiatr Res 37:165–169PubMedCrossRef

51.

Daniels TL, Cameron JL, Marcus MD, Berga SL (1997) Recovery from functional hypothalamic amenorrhea (FHA) involves resolution of hypothalamic hypothyroidism. In 79th Annual Meeting of The Endocrine Society. Minneapolis, MN

52.

Heer M, Mika C, Grzella I, Heussen N, Herpertz-Dahlmann B (2004) Bone turnover during inpatient nutritional therapy and outpatient follow-up in patients with anorexia nervosa compared with that in healthy control subjects. Am J Clin Nutr 80:774–781PubMed

53.

Viapiana O, Gatti D, Dalle Grave R, Todesco T, Rossini M, Braga V, Idolazzi L, Fracassi E, Adami S (2007) Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight. Bone 40:1073–1077PubMedCrossRef

54.

Dominguez J, Goodman L, Sen Gupta S, Mayer L, Etu SF, Walsh BT, Wang J, Pierson R, Warren MP (2007) Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses. Am J Clin Nutr 86:92–99PubMed

55.

Fredericson M, Kent K (2005) Normalization of bone density in a previously amenorrheic runner with osteoporosis. Med Sci Sports Exerc 37:1481–1486PubMedCrossRef

56.

Drinkwater BL, Nilson K, Ott S, Chesnut CH 3rd (1986) Bone mineral density after resumption of menses in amenorrheic athletes. JAMA 256:380–382PubMedCrossRef

57.

Drinkwater BL, Nilson K, Chesnut CH 3rd, Bremner WJ, Shainholtz S, Southworth MB (1984) Bone mineral content of amenorrheic and eumenorrheic athletes. N Engl J Med 311:277–281PubMedCrossRef

58.

Zanker CL, Cooke CB, Truscott JG, Oldroyd B, Jacobs HS (2004) Annual changes of bone density over 12 years in an amenorrheic athlete. Med Sci Sports Exerc 36:137–142PubMedCrossRef

59.

Compston JE, McConachie C, Stott C, Hannon RA, Kaptoge S, Debiram I, Love S, Jaffa A (2006) Changes in bone mineral density, body composition and biochemical markers of bone turnover during weight gain in adolescents with severe anorexia nervosa: a 1-year prospective study. Osteoporos Int 17:77–84PubMedCrossRef

60.

Bolton JG, Patel S, Lacey JH, White S (2005) A prospective study of changes in bone turnover and bone density associated with regaining weight in women with anorexia nervosa. Osteoporos Int 16:1955–1962PubMedCrossRef

61.

Miller KK, Lee EE, Lawson EA, Misra M, Minihan J, Grinspoon SK, Gleysteen S, Mickley D, Herzog D, Klibanski A (2006) Determinants of skeletal loss and recovery in anorexia nervosa. J Clin Endocrinol Metab 91:2931–2937PubMedCrossRef

62.

Satoh Y, Shimizu T, Lee T, Nishizawa K, Iijima M, Yamashiro Y (2003) Resting energy expenditure and plasma leptin levels in adolescent girls with anorexia nervosa. Int J Eat Disord 34:156–161PubMedCrossRef

63.

Van Wymelbeke V, Brondel L, Marcel Brun J, Rigaud D (2004) Factors associated with the increase in resting energy expenditure during refeeding in malnourished anorexia nervosa patients. Am J Clin Nutr 80:1469–1477PubMed

64.

Lob S, Pickel J, Bidlingmaier M, Schaaf L, Backmund H, Gerlinghoff M, Stalla GK (2003) Serum leptin monitoring in anorectic patients during refeeding therapy. Exp Clin Endocrinol Diabetes 111:278–282PubMedCrossRef

65.

Haas V, Onur S, Paul T, Nutzinger DO, Bosy-Westphal A, Hauer M, Brabant G, Klein H, Muller MJ (2005) Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery. Am J Clin Nutr 81:889–896PubMed

66.

Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnert P, Fichter M, Tschop M (2001) Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 145:669–673PubMedCrossRef

67.

Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N (2006) Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 91:3697–3710PubMedCrossRef

68.

Vestergaard P, Emborg C, Stoving RK, Hagen C, Mosekilde L, Brixen K (2003) Patients with eating disorders. A high-risk group for fractures. Orthop Nurs 22:325–331PubMedCrossRef

69.

Lucas AR, Melton LJ 3rd, Crowson CS, O’Fallon WM (1999) Long-term fracture risk among women with anorexia nervosa: a population-based cohort study. Mayo Clin Proc 74:972–977PubMed

70.

Cobb KL, Bachrach LK, Sowers M, Nieves J, Greendale GA, Kent KK, Brown BW Jr, Pettit K, Harper DM, Kelsey JL (2007) The effect of oral contraceptives on bone mass and stress fractures in female runners. Med Sci Sports Exerc 39:1464–1473PubMedCrossRef

Title: Strategies to reverse bone loss in women with functional hypothalamic amenorrhea: a systematic review of the literature
Authors: J. D. Vescovi
S. A. Jamal
M. J. De Souza
Publication date: 01-04-2008
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 4/2008
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-007-0518-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Strategies to reverse bone loss in women with functional hypothalamic amenorrhea: a systematic review of the literature

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2008

Salmon calcitonin: a review of current and future therapeutic indications

Does thoracic or lumbar spine bone architecture predict vertebral failure strength more accurately than density?

Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)

Experimental hip fracture load can be predicted from plain radiography by combined analysis of trabecular bone structure and bone geometry

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application